Recommendations for vaccination against shingles
DOI:
https://doi.org/10.12775/QS.2025.37.57705Keywords
shingles, vaccination, varicella-zoster virus, infectionAbstract
Introduction and purpose:
Shingles, or herpes zoster, is a painful condition caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. Vaccination is the most effective way to prevent shingles and its complications, including postherpetic neuralgia (PHN), a chronic and debilitating nerve pain condition. Vaccination is the most effective way to prevent shingles and its associated complications. This article provides an overview of current recommendations for shingles vaccination, including who should be vaccinated, the available vaccines, and key considerations.
Materials and methods:
A literature search was conducted by analysing scientific articles published in Google Scholar, PubMed, and UpToDate using keywords included: shingles, vaccination, varicella-zoster virus, infection. We also searched current recommendations of Centers for Disease Control and Prevention.
Description of the state of knowledge:
Shingles is a common condition, especially in older adults and those with weakened immune systems. While the disease itself can cause significant pain and discomfort, the risk of complications increases with age and other health conditions. Vaccination offers robust protection against shingles and its complications, reducing the overall health burden. Consulting a healthcare provider is advised to determine the best vaccination approach based on individual health conditions.
Conclusion:
Vaccination against shingles is a critical preventive measure for adults, particularly those aged 50 and older or individuals with weakened immune systems. Shingrix is the recommended vaccine due to its high efficacy and long-lasting protection. Patients should discuss their vaccination plans with healthcare provider to determine the optimal timing and ensure it aligns with their health needs. By staying proactive, individuals can significantly reduce their risk of shingles and enjoy better long-term health.
References
1. Schmader K.: Herpes zoster. Clin. Geriatr. Med., 2016; 32: 539–553.
2. John A.R., Canaday D.H.: Herpes zoster in the older adult. Infect. Dis. Clin. North Am., 2017; 31: 811–826.
3. Patil A., Goldust M., Wollina U.: Herpes zoster: A review of clinical manifestations and management. Viruses, 2022; 14: 192.
4. Shaikh S., Ta C.N.: Evaluation and management of herpes zoster ophthalmicus. Am. Fam. Physician, 2002; 66: 1723–1730.
5. Muecke M., Amedee R.G.: Herpes zoster oticus: diagnosis and management. J. La State Med. Soc., 1993; 145: 333–335.
6. Bakshi S.S., Ramesh S., Annam C.S.: Ramsay hunt syndrome. Am. J. Med., 2022; 135: e125–e126.
7. Chiriac A., Chiriac A.E., Podoleanu C., Stolnicu S.: Disseminated cutaneous herpes zoster – a frequently misdiagnosed entity. Int. Wound. J., 2020; 17: 1089–1091.
8. Johnson R.W., Alvarez-Pasquin M.-J., Bijl M. i wsp.: Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther. Adv. Vaccines, 2015; 3: 109–120.
9. Gross G.E., Eisert L., Doerr H.W. i wsp.: S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. JDDG J. Dtsch. Dermatol Ges., 2020; 18: 55–78.
10. Chen S.-Y., Suaya J.A., Li Q. i wsp.: Incidence of herpes zoster in patients with altered immune function. Infection, 2014; 42: 325–334.
11. Marra F., Parhar K., Huang B., Vadlamudi N.: Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect. Dis., 2020; 7: ofaa005.
12. Cui J., Zhang X., Zhu P. i wsp.: Effect of repetitive intracutaneous injections with local anesthetics and steroids for acute thoracic herpes zoster and incidence of postherpetic neuralgia. Pain Med., 2017; 18: 1566–1572.
13. Chen N., Li Q., Yang J. i wsp.: Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev., 2014; doi: 10.1002/14 651 858.CD006 866.pub3.
14. Werner R.N., Nikkels A.F. i wsp.: European consensus-based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J. Eur. Acad. Dermatol. Venereol., 2017; 31: 20–29.
15. Johnson R.W., Bouhassira D., Kassianos G. i wsp.: The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med., 2010; 8: 37.
16. Koshy E., Mengting L., Kumar H., Jianbo W. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J. Dermatol. Venereol. Leprol., 2018; 84: 251–262.
17. Dagnew A.F., Ilhan O., Lee W.-S. i wsp.: Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3 shingrix ded, clinical trial and post-hoc efficacy analysis. Lancet Infect. Dis., 2019; 19: 988–1000.
18. Vink P., Ramon Torrell J.M., Sanchez Fructuoso A. i wsp.: Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin. Infect. Dis., 2020; 70: 181–190.
19. Gabutti G., Valente N., Sulcaj N., Stefanati A.: Evaluation of efficacy and effectiveness of live attenuated zoster vaccine. J. Prev. Med. Hyg., 2014; 55: 130–136.
20. Matthews S., De Maria A., Passamonti M. i wsp.: The economic burden and impact on quality of life of herpes zoster and postherpetic neuralgia in individuals aged 50 years or older in Italy. Open Forum Infect. Dis., 2019; doi: 10.1093/ofid/ofz007.
21. Henze L., Buhl C., Sandherr M. i wsp.: Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann. Hematol., 2022; 101: 491–511.
22. Marra F., Lo E., Kalashnikov V., Richardson K.: Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect. Dis., 2016; 3: ofw205.
23. Bollaerts K., Riera-Montes M., Heininger U. i wsp.: A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol. Infect., 2017, 145: 2666–2677.
24. Godeaux O., Kovac M., Shu D. i wsp.: Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ? 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum. Vaccin. Immunother., 2017; 13: 1051–1058.
25. Kim Y.J., Lee C.N., Lee M.S. i wsp.: Recurrence rate of herpes zoster and its risk factors: a population-based cohort study. J. Korean Med. Sci., 2018; doi: 10.3346/jkms.2019.34.e1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zuzanna Wyleciał, Eliza Pyla, Wiktoria Zamachowska, Julia Ząber
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 237
Number of citations: 0
